세계 급성 림프구성 백혈병 시장 : 유형별, 치료법별, 연령층별, 투여 경로별, 진단별, 최종 사용자별 및 지역별 분석(-2030년)

According to Stratistics MRC, the Global Acute Lymphoblastic Leukaemia (ALL) Market is accounted for $2.67 billion in 2023 and is expected to reach $4.17 billion by 2030 growing at a CAGR of 6.6% during the forecast period. A cancerous condition called acute lymphoblastic leukemia (ALL) arises from immature lymphocytes. Acute refers to leukemia that advances swiftly and disseminates throughout the body. The development of ALL begins in the bone marrow and spreads fast to the liver, spleen, lymph nodes, liver, central nervous system, spleen, and blood. Weight loss, shortness of breath, lack of appetite, paler complexion, bruises, frequent and severe bleeding gums, and nasal bleeds are only a few examples of non-specific symptoms.

According to the American Cancer Society research, acute lymphocytic leukemia in the US for 2023 is about 6,540 new cases, of which 3,660 were male and 2,880 females. The mortality is about 1,390 700 in males and 690 in females.

Market Dynamics:

Driver:

Increasing geriatric population

The need for healthcare services, such as prescription drugs, long-term care, and medical treatments, is increasing as the world's population continues to age. Healthcare providers and pharmaceutical firms now have the chance to meet the demands of the senior population thanks to this demographic shift. Due to age-related diseases and chronic ailments, older people frequently demand an additional healthcare service, which propels the sector's growth.

Restraint:

Regulatory challenges in healthcare

The difficult and constantly shifting regulatory environment is one of the biggest obstacles facing the healthcare sector. Health care laws differ from nation to nation and are often updated. For healthcare providers and pharmaceutical firms, navigating regulatory issues can take time and money, which might delay the creation and provision of novel medicines and services. The healthcare sector's ability to expand and innovate may be hampered by this regulatory load.

Opportunity:

Growing government initiatives

Numerous government agencies are taking steps to create campaigns where modern cancer medicines are employed to find cancer cells and aid individuals in curing themselves of the disease. Government funding is also given to a number of medical research organizations, which aid pharmaceutical companies in creating cutting-edge cancer treatment technology and medications. This aspect has increased market demand over time.

Threat:

Side effects & adverse reactions

Despite the benefits of leukemia treatment items, unfavorable responses and side effects are anticipated to constrain market expansion. A variety of therapies can have negative side effects, such as chemotherapy, which can cause infections, skin conditions, hair loss, and other issues. Adverse effects from targeted therapy might include nausea, diarrhea, hair loss, and liver issues. Additionally, various treatment options have certain side effects that might reduce the pace at which leukemia therapeutic solutions are adopted.

COVID-19 Impact:

The COVID-19 has had both beneficial and negative effects on the healthcare sector. Lockdowns were enacted by the governments, which caused an imbalance in the supply and demand of pharmaceutical items in the healthcare industry. The majority of businesses have manufacturing operations in important nations, where the pandemic has had a big impact on business revenues for a variety of healthcare items. However, important illnesses including cancer, cardiovascular disease, and other serious medical issues have received regular care. Sales of treatment products for leukemia have been slightly impacted by the epidemic.

The chemotherapy segment is expected to be the largest during the forecast period

The chemotherapy segment is expected to be the largest during the forecast period. This is because it has the ability to destroy leukemia cells and prevent malignant cells from proliferating and replicating, slowing the spread of the disease. ALL is treated with chemotherapy using drugs with a single impact or several effects. Cytotoxic substances, antimetabolites, alkylating substances, and other plant derivatives are all used in this treatment.

The pediatrics segment is expected to have the highest CAGR during the forecast period

The pediatrics segment is expected to have the highest CAGR during the forecast period. The high prevalence of acute lymphocytic/lymphoblastic leukemia in the pediatric population is to blame for this. One of the most prevalent cancer forms in children is acute lymphoblastic leukemia. Additionally, the success rate of therapy for acute lymphoblastic leukemia is greater in the pediatric population.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. The key factors that contribute to its huge market share are the existence of significant manufacturers in the United States, together with a well-established healthcare infrastructure and technological innovation. Additionally, expanding private healthcare organizations and consumers with high buying power are projected to fuel market expansion throughout the projection period.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to its high population base and rise in patient awareness toward cancer care. This is due to an increase in the number of medications for treatment receiving approval, as well as increased efforts by the government and pharmaceutical companies to raise awareness of the condition in this area. During the projected period, rising government spending on healthcare is likely to drive the market.

Key players in the market:

Some of the key players in Acute Lymphoblastic Leukaemia Market include: Amgen, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Jazz Pharmaceuticals, Erytech Pharma, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Genzyme Corporation, GlaxoSmithKline Plc., Kite Pharma, Inc., Novartis AG, Pfizer Inc., Sanofi, Leadiant Biosciences Inc., Spectrum Pharmaceuticals Inc., Thermo Fisher Scientific Inc. and Baxter International Inc.

Key Developments:

In October 2023, Thermo Fisher Scientific Inc. announced the completion of its acquisition of The Binding Site Group, a global leader in specialty diagnostics. The acquisition will aid in the growth of the specialty diagnostics market.

In July 2023, the introduction of PERCLOT Absorbable Hemostatic Powder in the U.S. was announced by Baxter International Inc., a leader in advancing surgical innovation worldwide. For patients with intact coagulation, PERCLOT is a passive, absorbable hemostatic powder that is ready to use and intended to stop minor bleeding

In June 2023, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL).

Types Covered:

• T-cell Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Philadelphia Chromosome
• Other Types

Treatments Covered:

• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Bone Marrow Transplant
• Chemotherapy
• Stem Cell Transplantation
• Other Treatments

Age Groups Covered:

• Adults
• Pediatrics

Route of Administrations Covered:

• Injectable
• Oral

Diagnosis Covered:

• Spinal Tap and Cerebrospinal Fluid (CSF) Analysis
• Bone Marrow Aspiration and Biopsy
• Immunophenotyping
• Complete Blood Count (CBC) and Differential
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Minimal Residual Disease (MRD) Testing
• Other Diagnosis

End Users Covered:

• Clinics
• Hospitals
• Retail Pharmacy
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Acute Lymphoblastic Leukemia Market, By Type

• 5.1 Introduction
• 5.2 T-cell Lymphoblastic Leukemia
• 5.3 B-cell Acute Lymphoblastic Leukemia
• 5.4 Philadelphia Chromosome
• 5.5 Other Types

6 Global Acute Lymphoblastic Leukemia Market, By Treatment

• 6.1 Introduction
• 6.2 Radiation Therapy
• 6.3 Targeted Therapy
• 6.4 Immunotherapy
• 6.5 Bone Marrow Transplant
• 6.6 Chemotherapy
• 6.7 Stem Cell Transplantation
• 6.8 Other Treatments

7 Global Acute Lymphoblastic Leukemia Market, By Age Group

• 7.1 Introduction
• 7.2 Adults
• 7.3 Pediatrics

8 Global Acute Lymphoblastic Leukemia Market, By Route of Administration

• 8.1 Introduction
• 8.2 Injectable
• 8.3 Oral

9 Global Acute Lymphoblastic Leukemia Market, By Diagnosis

• 9.1 Introduction
• 9.2 Spinal Tap and Cerebrospinal Fluid (CSF) Analysis
• 9.3 Bone Marrow Aspiration and Biopsy
• 9.4 Immunophenotyping
• 9.5 Complete Blood Count (CBC) and Differential
• 9.6 Flow Cytometry
• 9.7 Polymerase Chain Reaction (PCR)
• 9.8 Next-Generation Sequencing (NGS)
• 9.9 Minimal Residual Disease (MRD) Testing
• 9.10 Other Diagnosis

10 Global Acute Lymphoblastic Leukemia Market, By End User

• 10.1 Introduction
• 10.2 Clinics
• 10.3 Hospitals
• 10.4 Retail Pharmacy
• 10.5 Other End Users

11 Global Acute Lymphoblastic Leukemia Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Amgen, Inc.
• 13.2 Bristol-Myers Squibb Company
• 13.3 Celgene Corporation
• 13.4 Jazz Pharmaceuticals
• 13.5 Erytech Pharma
• 13.6 GlaxoSmithKline Plc.
• 13.7 F. Hoffmann-La Roche Ltd.
• 13.8 Genzyme Corporation
• 13.9 GlaxoSmithKline Plc.
• 13.10 Kite Pharma, Inc.
• 13.11 Novartis AG
• 13.12 Pfizer Inc.
• 13.13 Sanofi
• 13.14 Leadiant Biosciences Inc.
• 13.15 Spectrum Pharmaceuticals Inc.
• 13.16 Thermo Fisher Scientific Inc.
• 13.17 Baxter International Inc.